tetano
Editor, Senior Moderator
J Neuroimmunol
. 2021 Dec 9;362:577785.
doi: 10.1016/j.jneuroim.2021.577785. Online ahead of print.
New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
Karlo Toljan[SUP] 1 [/SUP], Moein Amin[SUP] 1 [/SUP], Amy Kunchok[SUP] 2 [/SUP], Daniel Ontaneda[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case.
Conclusion: Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis.
Keywords: COVID-19; COVID-19 vaccines; Coronavirus; Diagnosis; Multiple sclerosis; SARS-CoV-2; Vaccination.
. 2021 Dec 9;362:577785.
doi: 10.1016/j.jneuroim.2021.577785. Online ahead of print.
New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
Karlo Toljan[SUP] 1 [/SUP], Moein Amin[SUP] 1 [/SUP], Amy Kunchok[SUP] 2 [/SUP], Daniel Ontaneda[SUP] 3 [/SUP]
Affiliations
- PMID: 34922126
- DOI: 10.1016/j.jneuroim.2021.577785
Abstract
Background: Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case.
Conclusion: Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis.
Keywords: COVID-19; COVID-19 vaccines; Coronavirus; Diagnosis; Multiple sclerosis; SARS-CoV-2; Vaccination.
Last edited by a moderator: